An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The purpose of this expanded access program (EAP) is to provide early access to divarasib to participants with KRAS G12C-positive (KRAS G12C+) advanced or metastatic non-small cell lung cancer (NSCLC), prior to divarasib becoming commercially available in the United States.
Epistemonikos ID: 5ad4e4be5437a44d326b9e0f984a72c9c58610c8
First added on: Aug 26, 2026